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20a Sunday, February 8, 2015epithelium prone to infection and in intestine leads to obstruction. Patients ho-
mozygous for F508del, have a tremendous variation in the severity of disease.
Recent Genome-wide association studies indicate that this variation is due to
presence of modifier genes, with SLC6A14 as the top modifier (Sun
et.al.,2012). SLC6A14 is a Naþ/Cl- dependent cationic/neutral amino-acid
transporter on the surface of lung and colonic epithelium. As both transporters
are expressed apically, we hypothesized that SLC6A14 would modify the fluid
secretory capacity of the epithelium. So in collaboration with TCP, we gener-
ated a SLC6A14 knock-out mouse. We can measure in-vivo fluid secretion in
mice, using an intestinal closed-loop assay. SLC6A14 knock-out mice ex-
hibited a decrease in cAMP stimulated fluid secretion mediated via CFTR rela-
tive to Wt control. To explore the mechanism by which this modification
occurs, we utilized a BHK heterologous expression system, overexpressing
CFTR and SLC6A14. Interestingly, the functional interaction can be recapitu-
lated in this system, suggesting that it not tissue-type dependent. Preliminary
biochemical and anion-flux studies support the hypothesis that SLC6A14
does not affect the processing or stability of Wt or F508del-CFTR proteins
rather it augments the activity of these channel proteins once localized to the
cell surface. Future studies will focus on understanding if this augmentation
is related to modification of CFTR’s phosphorylation dependent gating. These
results show a positive impact of SLC6A14 on CFTR channel function and
fluid secretion, providing an alternative drug target for CF patients.
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HVCN1 is the only mammalian voltage-gated proton channel. In human B lym-
phocytes, HVCN1 associates with the B Cell Receptor (BCR) and is required
for optimal BCR signaling and redox control. HVCN1 is expressed in malig-
nant B cells that rely on BCR signaling, such as Chronic Lymphocytic Leuke-
mia (CLL) cells. Compared with normal B lymphocytes, HVCN1S expression
is higher in B-cell lines and in B cells from patients with Chronic Lymphocytic
Leukemia. We found that HVCN1 was expressed in B cells as two protein iso-
forms. The shorter isoform (HVCN1S) was enriched in B cells from a cohort of
76 CLL patients. When overexpressed in a B-cell lymphoma line, HVCN1S re-
sponded more profoundly to PKC-dependent phosphorylation. This more
potent enhanced gating response was mediated by increased phosphorylation
of the same residue responsible for enhanced gating in HVCN1L, Thr
29.
Although B cells from CLL patients expressed both isoforms, their PMA
response was comparable with that of cells heterologously expressing HVCN1S
alone, indicating that this isoform dominates. Furthermore, the association of
HVCN1S with the BCR was weaker, which resulted in its diminished internal-
ization upon BCR stimulation. Finally, HVCN1S conferred a proliferative and
migratory advantage, as well as enhanced BCR-dependent signaling. Overall,
our data show for the first time the existence of a shorter isoform of HVCN1
with enhanced gating that is specifically enriched in malignant B cells.
HVCN1S properties suggest it may contribute to the pathogenesis of BCR
dependent B-cell malignancies.
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GSK Oncology - BBSRC CASE PhD studentship (MB); NIH grant
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Small-conductance (KCa2) and intermediate-conductance (KCa3.1) calcium-
activated Kþ channels are voltage-independent and share a common calcium/
calmodulin mediated gating mechanism. Existing positive gating modulators
like EBIO, NS309 or SKA-31 activate both KCa2 and KCa3.1 channels with
similar potency or, as in the case of CyPPA and NS13001, selectively activate
KCa2.2 and KCa2.3 channels. We recently performed a structure activity rela-tionship (SAR) study with the aim of optimizing the benzothiazole pharmaco-
phore of SKA-31 towards KCa3.1 selectivity and have identified SKA-121
(5-methylnaphtho[2,1-d]oxazol-2-amine), which displays 41-fold selectivity
for KCa3.1 (EC50 109 nM 5 14 nM) over KCa2.3 (EC50 4.4 5 1.6 mM).
SKA-121 is 200-400 fold selective over representative KV (KV1.3, KV2.1,
KV3.1 and KV11.1), NaV (NaV1.2, NaV1.4, NaV1.5 and NaV1.7) as well
as CaV1.2 channels. SKA-121 is a typical positive-gating modulator, which
shifts the calcium-concentration response curve of KCa3.1 to the left but
also increases open probability at saturating Ca2þ concentrations. In order to
understand why introduction of a ‘‘simple’’ CH3 group in 5-position of the ben-
zothiazole/oxazol system could achieve such a significant gain in selectivity for
KCa3.1 over KCa2.3 we are currently performing site-directed mutagenesis of
the calmodulin binding domain (CaMBD) guided by structural modeling. We
used the RosettaLigand method to generate preliminary models of SKA-121
binding to our model of the KCa3.1 C-terminal CaMBD in complex with
calmodulin. Our most energetically favorable model suggests that SKA-121
is positioned in close proximity to F301, R362, V365, M368, V369, and
S372 in KCa3.1.
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Microglia rapidly respond to CNS injury and disease and can assume a spec-
trum of activation states that are reflected by changes in gene expression. Clas-
sical activation (often induced by lipopolysaccharide) and alternative activation
(IL4-induced) are now well studied but less is known about acquired de-
activation in response to IL10. Here, we are addressing how microglial
activation states affect their migration and invasion; crucial functions in the
developing CNS and after injury in adults.
We found that LPS-treated rat microglia migrate very poorly; whereas, IL4- or
IL10-treated cells migrated and invaded much better than resting cells. Never-
theless, there were similarities and differences in gene induction by IL4 and
IL10. The lamellum of migrating microglia contains a large ring of podoso-
mes_microscopic structures that are thought to mediate adhesion, migration
and invasion. IL10 (not IL4) increased podosome expression.
Then, based on the observed enrichment of SK3 Ca2þ-activated potassium
channels in podosomes, we predicted that it regulates migration and invasion.
KCNN3 (SK3) expression was similar under all three activation conditions and
KCa2.3 currents were observed. A surprising finding was that, of the three SK3
inhibitors tested (apamin, tamapin, NS8593); only NS8593 reduced the migra-
tion and invasion of IL4- or IL10-activated microglia. Surprisingly, in addition
to blocking SK3, we found that NS8593 blocked TRPM7 channels in micro-
glia. We confirmed that TRPM7 (not SK3) regulates migration and invasion
by using a TRPM7 inhibitor (AA-861) that does not block SK3 channels.
We conclude that TRPM7 (not SK3) contributes to the enhanced ability of mi-
croglia to migrate and invade when in anti-inflammatory states. This will be an
important consideration in the current efforts to develop TRPM7 inhibitors for
treating CNS injury.
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Retigabine is the prototypical member of a recently discovered class of anti-
epileptic drugs that act by potentiating the neuronal M-current formed by
KCNQ2-5 potassium channel subunits. Retigabine interacts with the pore of
KCNQ2-5 channels, requiring a Trp residue present in KCNQ2-5 to exert its
effects, suggesting the notion of a hydrophobic binding pocket. We have
used nonsense suppression to subtly alter the properties of this Trp residue
(265) in homomeric KCNQ3 channels and identify the specific chemical inter-
actions required for retigabine effects. Remarkably, simply changing the posi-
tion of the indole nitrogen atom from Trp265 (removing its hydrogen bonding
